Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Year: 2014
Type: article
Abstract: In patients with multiple myeloma (MM) not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), the 2 following options are recommended as part of front-line treatment and approved based on data from randomized phase III trials: melphalan/prednisone/thalidomide (MPT), or
Source: Haematologica
Authors: P. Rodon, C. Hulin, B. Pegourie, M. Tiab, B. Anglaret, L. Benboubker, H. Jardel, O. Decaux, B. Kolb, M. Roussel, L. Garderet, X. Leleu, O. Fitoussi, C. Chaleteix, P. Casassus, P. Lenain, B. Royer, A. Banos, R. Benramdane, P. Cony-Makhoul, M. Dib, J. Fontan, A.-M. Stoppa, C. Traulle, J.-P. Vilque, M.-O. Petillon, C. Mathiot, T. Dejoie, H. Avet-Loiseau, P. Moreau
Institutions: Centre Hospitalier Régional et Universitaire de Nancy, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Départemental Vendée, Centre Hospitalier de Valence, Centre Hospitalier Universitaire de Tours, Centre hospitalier Bretagne Atlantique, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier Universitaire de Reims, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Centre Hospitalier Universitaire de Lille, Polyclinique Bordeaux Nord Aquitaine, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Avicenne, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier de la Côte Basque, Hôpital NOVO, Centre Hospitalier Universitaire de Besançon, Institut Paoli-Calmettes, Centre François Baclesse, Institut Curie, Centre Hospitalier Universitaire de Nantes, Nantes Université
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2059895867
